[go: up one dir, main page]

AU2003269257A1 - Use of cap-1 for the therapy of asthma - Google Patents

Use of cap-1 for the therapy of asthma

Info

Publication number
AU2003269257A1
AU2003269257A1 AU2003269257A AU2003269257A AU2003269257A1 AU 2003269257 A1 AU2003269257 A1 AU 2003269257A1 AU 2003269257 A AU2003269257 A AU 2003269257A AU 2003269257 A AU2003269257 A AU 2003269257A AU 2003269257 A1 AU2003269257 A1 AU 2003269257A1
Authority
AU
Australia
Prior art keywords
asthma
therapy
cap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003269257A
Other versions
AU2003269257A8 (en
Inventor
Kevin Bruce Bacon
Herath Mudiyanselage Athula Chandrasiri Herath
Ningshu Liu
Peter Reinemer
Christian Rohlff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2003269257A8 publication Critical patent/AU2003269257A8/en
Publication of AU2003269257A1 publication Critical patent/AU2003269257A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003269257A 2002-10-08 2003-10-08 Use of cap-1 for the therapy of asthma Abandoned AU2003269257A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0223272A GB0223272D0 (en) 2002-10-08 2002-10-08 A protein involved in therapy
GB0223272.6 2002-10-08
PCT/GB2003/004341 WO2004034062A2 (en) 2002-10-08 2003-10-08 Use of cap-1 for the therapy of asthma

Publications (2)

Publication Number Publication Date
AU2003269257A8 AU2003269257A8 (en) 2004-05-04
AU2003269257A1 true AU2003269257A1 (en) 2004-05-04

Family

ID=9945455

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003269257A Abandoned AU2003269257A1 (en) 2002-10-08 2003-10-08 Use of cap-1 for the therapy of asthma

Country Status (3)

Country Link
AU (1) AU2003269257A1 (en)
GB (1) GB0223272D0 (en)
WO (1) WO2004034062A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011143776A (en) * 2009-03-30 2013-05-10 Протаб Лтд. PROTEIN ASSOCIATED WITH Adenylyl cyclase (CAP1) AND USE IT AS A TARGET FOR IMMUNOMODULATION
US9933424B2 (en) 2011-08-08 2018-04-03 Seoul National University Hospital Human resistin receptor and use thereof
WO2013022262A2 (en) * 2011-08-08 2013-02-14 서울대학교병원 Human resistin receptor, and use thereof
US12410219B2 (en) 2017-01-31 2025-09-09 Seoul National University Hospital Polypeptide derived from CAP1 and pharmaceutical composition comprising same as effective ingredient
KR102040974B1 (en) * 2017-01-31 2019-11-06 서울대학교병원 Polypeptides that were derived from adenylyl cyclase-associated protein 1(CAP1) and pharmaceutical composition comprising the same
CA3170560A1 (en) * 2020-03-02 2021-09-10 Seoul National University Hospital Pharmaceutical composition for lowering blood cholesterol, preventing or treating cardiovascular diseases and reducing inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271536A1 (en) * 2000-06-29 2002-01-14 Incyte Genomics, Inc. Adenylyl and guanylyl cyclases
AU2002237228A1 (en) * 2000-12-11 2002-06-24 Bayer Aktiengesellschaft Regulation of human adenylate cyclase, type vii
US6706688B2 (en) * 2001-03-09 2004-03-16 Paula Sundstrom Methods for regulating bud-hypha transitions and cAMP levels by the adenylate cyclase-associated protein gene, CAP1
GB0213964D0 (en) * 2002-06-18 2002-07-31 Oxford Glycosciences Uk Ltd Protein

Also Published As

Publication number Publication date
AU2003269257A8 (en) 2004-05-04
WO2004034062A2 (en) 2004-04-22
GB0223272D0 (en) 2002-11-13
WO2004034062A3 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
AU2003279338A1 (en) Phenethanolamine derivatives for the treatment of respiratory diseases
AU2003285091A1 (en) Interferon antagonists useful for the treatment of interferon related diseases
AU2003286567A1 (en) Methods for the treatment of skin disorders
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
AU2003300791A1 (en) Combination therapy for the treatment of pain
PT1530466E (en) Use of nintedanib for the treatment of lung fibrosis
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU2003247005A1 (en) Therapy combination
AU2001293891A1 (en) New combination for the treatment of asthma
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
AU2003251875A1 (en) Combination therapy for the treatment of neoplasms
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
AU2003269257A1 (en) Use of cap-1 for the therapy of asthma
AU2003205898A1 (en) Combination therapy for respiratory disorders
AU2002335667A1 (en) Modified reoviral therapy
AU2003296545A1 (en) Use of a trpm8-activating substance for the treatment of tumours
AU2003278420A1 (en) Process for the preparation of ganciclovir
AU3064800A (en) The therapeutic use of r-warfarin as anticoagulant
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase